Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
| # | Name | Date |
|---|---|---|
| 1 | 202317037743-STATEMENT OF UNDERTAKING (FORM 3) [01-06-2023(online)].pdf | 2023-06-01 |
| 2 | 202317037743-Sequence Listing in txt [01-06-2023(online)].txt | 2023-06-01 |
| 3 | 202317037743-Sequence Listing in PDF [01-06-2023(online)].pdf | 2023-06-01 |
| 4 | 202317037743-REQUEST FOR EXAMINATION (FORM-18) [01-06-2023(online)].pdf | 2023-06-01 |
| 5 | 202317037743-PROOF OF RIGHT [01-06-2023(online)].pdf | 2023-06-01 |
| 6 | 202317037743-POWER OF AUTHORITY [01-06-2023(online)].pdf | 2023-06-01 |
| 7 | 202317037743-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [01-06-2023(online)].pdf | 2023-06-01 |
| 8 | 202317037743-FORM 18 [01-06-2023(online)].pdf | 2023-06-01 |
| 9 | 202317037743-FORM 1 [01-06-2023(online)].pdf | 2023-06-01 |
| 10 | 202317037743-DECLARATION OF INVENTORSHIP (FORM 5) [01-06-2023(online)].pdf | 2023-06-01 |
| 11 | 202317037743-COMPLETE SPECIFICATION [01-06-2023(online)].pdf | 2023-06-01 |
| 12 | 202317037743-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [01-06-2023(online)].pdf | 2023-06-01 |
| 13 | 202317037743.pdf | 2023-06-16 |
| 14 | 202317037743-RELEVANT DOCUMENTS [19-07-2023(online)].pdf | 2023-07-19 |
| 15 | 202317037743-FORM 13 [19-07-2023(online)].pdf | 2023-07-19 |
| 16 | 202317037743-FORM 3 [16-11-2023(online)].pdf | 2023-11-16 |